| D008595 |
Menorrhagia |
Excessive uterine bleeding during MENSTRUATION. |
Hypermenorrhea,Heavy Menstrual Bleeding,Heavy Periods,Heavy Period,Menstrual Bleeding, Heavy |
|
| D008656 |
Mestranol |
The 3-methyl ether of ETHINYL ESTRADIOL. It must be demethylated to be biologically active. It is used as the estrogen component of many combination ORAL CONTRACEPTIVES. |
19-Norpregna-1,3,5(10)-trien-20-yn-17-ol, 3-methoxy-, (17alpha)-,Ethinyl Estradiol 3-Methyl Ether,Ethinyl Estradiol 3 Methyl Ether |
|
| D008796 |
Metrorrhagia |
Abnormal uterine bleeding that is not related to MENSTRUATION, usually in females without regular MENSTRUAL CYCLE. The irregular and unpredictable bleeding usually comes from a dysfunctional ENDOMETRIUM. |
Bleeding Between Periods,Breakthrough Bleeding,Dysfunctional Uterine Bleeding,Intermenstrual Bleeding,Spotting,Bleeding, Breakthrough,Dysfunctional Uterine Bleedings,Uterine Bleeding, Dysfunctional |
|
| D008875 |
Middle Aged |
An adult aged 45 - 64 years. |
Middle Age |
|
| D009640 |
Norethindrone |
A synthetic progestational hormone with actions similar to those of PROGESTERONE but functioning as a more potent inhibitor of ovulation. It has weak estrogenic and androgenic properties. The hormone has been used in treating amenorrhea, functional uterine bleeding, endometriosis, and for CONTRACEPTION. |
19-Norpregn-4-en-20-yn-3-one, 17-hydroxy-, (17alpha)-,Ethinylnortestosterone,Norethisterone,Norpregneninolone,Conceplan,Micronor,Monogest,Nor-QD,Norcolut,Norcolute,Norethindrone, (1 beta)-Isomer,Norlutin,Nor QD,NorQD |
|
| D002979 |
Climacteric |
Physiologic period, characterized by endocrine, somatic, and psychic changes with the termination of ovarian function in the female. It may also accompany the normal diminution of sexual activity in the male. |
Change of Life,Climacterics,Life Change,Life Changes |
|
| D002986 |
Clinical Trials as Topic |
Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries. |
Clinical Trial as Topic |
|
| D004338 |
Drug Combinations |
Single preparations containing two or more active agents, for the purpose of their concurrent administration as a fixed dose mixture. |
Drug Combination,Combination, Drug,Combinations, Drug |
|
| D004341 |
Drug Evaluation |
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. |
Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation |
|
| D005260 |
Female |
|
Females |
|